{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3569, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/9SJ4fBlSyXwB7ReAYr2dYBo2Vwh6n9pVSJA17skn1CA/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MTBlODM1NWMzYjEyNGIwNjJhNDQ5ZDZiMzg0OGJhOS9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/1", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "c782c61d-73a9-406f-a0bd-432431ac0857", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "Introduction to Immix Biopharma and its focus on oncology and immunology", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": "https://imgproxy.kitesheet.com/XA4utuTkfOBH4MwEtJhmfVp5cCFW3qK7CKduG67iz38/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MTBlODM1NWMzYjEyNGIwNjJhNDQ5ZDZiMzg0OGJhOS9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/7_W1NxoTAyorELjegNzZgr4vz78lWpkc3ZMrvYLcZd8/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MTBlODM1NWMzYjEyNGIwNjJhNDQ5ZDZiMzg0OGJhOS9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/vFE6JKcZZPEcygABMsVdPqyFeelgsFi95SnCKTK5W8Q/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MTBlODM1NWMzYjEyNGIwNjJhNDQ5ZDZiMzg0OGJhOS9wMDAxLnBuZw" }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/2", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-2", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "c782c61d-73a9-406f-a0bd-432431ac0857", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "Introduction to Immix Biopharma and its focus on oncology and immunology", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "executive_summary", "function": "summarize", "notes": "The slide uses a numbered list format to present key value propositions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/3", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-3", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "c782c61d-73a9-406f-a0bd-432431ac0857", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "Introduction to Immix Biopharma and its focus on oncology and immunology", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "executive_summary", "function": "summarize", "notes": "The slide highlights two distinct pipelines: N-GENIUS (cell therapy) and SMARxT (tissue-specific).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/4", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "c782c61d-73a9-406f-a0bd-432431ac0857", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "Introduction to Immix Biopharma and its focus on oncology and immunology", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a stylized area chart to represent market segments and their associated financial opportunities.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/5", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-5", "loopMatches": [], "arcBeatMatches": [ { "to": 7, "from": 5, "beatId": "4b86493a-1393-464b-b6ad-158ad0028028", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "Discussion of current problems with BCMA CAR-T therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "roadmap", "function": "show_traction", "notes": "The table uses a standard pharmaceutical pipeline layout with clinical and preclinical segments.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/6", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-6", "loopMatches": [], "arcBeatMatches": [ { "to": 7, "from": 5, "beatId": "4b86493a-1393-464b-b6ad-158ad0028028", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "Discussion of current problems with BCMA CAR-T therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "problem_statement", "function": "frame_problem", "notes": "The slide uses a hub-and-spoke diagram to illustrate the negative consequences of neurotoxicity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/7", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-7", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 7, "from": 5, "beatId": "4b86493a-1393-464b-b6ad-158ad0028028", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "Discussion of current problems with BCMA CAR-T therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "solution", "function": "present_solution", "notes": "Includes a cartoon liver character, likely representing the target organ or safety profile.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/8", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-8", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 21, "from": 8, "beatId": "a874b208-4408-43df-9863-8c8c163ed01d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Presentation of clinical data and competitive analysis for NXC-201", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "Includes extensive disclaimer text regarding cross-trial comparison limitations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/9", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-9", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 21, "from": 8, "beatId": "a874b208-4408-43df-9863-8c8c163ed01d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Presentation of clinical data and competitive analysis for NXC-201", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "Includes detailed source citations in the footer.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/10", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-10", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 21, "from": 8, "beatId": "a874b208-4408-43df-9863-8c8c163ed01d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Presentation of clinical data and competitive analysis for NXC-201", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "Includes detailed source citations in the footer; uses a color-coded legend for different drug treatments.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/11", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-11", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 21, "from": 8, "beatId": "a874b208-4408-43df-9863-8c8c163ed01d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Presentation of clinical data and competitive analysis for NXC-201", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a two-column layout to separate milestones by drug candidate.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/12", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-12", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 21, "from": 8, "beatId": "a874b208-4408-43df-9863-8c8c163ed01d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Presentation of clinical data and competitive analysis for NXC-201", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "solution", "function": "present_solution", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/13", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-13", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 21, "from": 8, "beatId": "a874b208-4408-43df-9863-8c8c163ed01d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Presentation of clinical data and competitive analysis for NXC-201", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/14", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-14", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 21, "from": 8, "beatId": "a874b208-4408-43df-9863-8c8c163ed01d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Presentation of clinical data and competitive analysis for NXC-201", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a table structure to contrast clinical outcomes across three key value pillars: response rates, tolerability, and outpatient feasibility.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/15", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-15", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 21, "from": 8, "beatId": "a874b208-4408-43df-9863-8c8c163ed01d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Presentation of clinical data and competitive analysis for NXC-201", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "solution", "function": "present_solution", "notes": "Includes comparative data points for transduction efficiency and experimental data for tonic signaling and anti-exhaustion.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/16", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-16", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 21, "from": 8, "beatId": "a874b208-4408-43df-9863-8c8c163ed01d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Presentation of clinical data and competitive analysis for NXC-201", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "why_now", "function": "argue_timing", "notes": "Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs. competitors.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/17", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-17", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 21, "from": 17, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "937d5537-d54e-4e3a-a66e-a14f52ce0de8", "evidence": "Discussion of NXC-201 entering large markets at a pivotal moment", "position": 2, "objective": "Explaining the timing of NXC-201's entry into the market", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [ { "to": 21, "from": 8, "beatId": "a874b208-4408-43df-9863-8c8c163ed01d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Presentation of clinical data and competitive analysis for NXC-201", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/18", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-18", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 21, "from": 17, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "937d5537-d54e-4e3a-a66e-a14f52ce0de8", "evidence": "Discussion of NXC-201 entering large markets at a pivotal moment", "position": 2, "objective": "Explaining the timing of NXC-201's entry into the market", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [ { "to": 21, "from": 8, "beatId": "a874b208-4408-43df-9863-8c8c163ed01d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Presentation of clinical data and competitive analysis for NXC-201", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a two-column layout to contrast clinical results for Multiple Myeloma vs. AL Amyloidosis, supported by market data for existing therapies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/19", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-19", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 21, "from": 17, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "937d5537-d54e-4e3a-a66e-a14f52ce0de8", "evidence": "Discussion of NXC-201 entering large markets at a pivotal moment", "position": 2, "objective": "Explaining the timing of NXC-201's entry into the market", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [ { "to": 21, "from": 8, "beatId": "a874b208-4408-43df-9863-8c8c163ed01d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Presentation of clinical data and competitive analysis for NXC-201", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/20", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-20", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 21, "from": 17, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "937d5537-d54e-4e3a-a66e-a14f52ce0de8", "evidence": "Discussion of NXC-201 entering large markets at a pivotal moment", "position": 2, "objective": "Explaining the timing of NXC-201's entry into the market", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [ { "to": 21, "from": 8, "beatId": "a874b208-4408-43df-9863-8c8c163ed01d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Presentation of clinical data and competitive analysis for NXC-201", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a red dashed box to highlight the core clinical data rows for comparison.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/21", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-21", "loopMatches": [ { "to": 21, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8", "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies", "position": 0, "objective": "Highlighting the need for improved therapies", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 21, "from": 17, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "937d5537-d54e-4e3a-a66e-a14f52ce0de8", "evidence": "Discussion of NXC-201 entering large markets at a pivotal moment", "position": 2, "objective": "Explaining the timing of NXC-201's entry into the market", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [ { "to": 21, "from": 8, "beatId": "a874b208-4408-43df-9863-8c8c163ed01d", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Presentation of clinical data and competitive analysis for NXC-201", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "traction", "function": "show_traction", "notes": "The chart demonstrates deepening clinical responses over time for NXC-201 therapy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/22", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-22", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "appendix_data", "function": "analyze_data", "notes": "The table uses a red dashed box to highlight the core clinical data rows.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/23", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-23", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide highlights specific safety data points for a competitor product to establish a benchmark.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/24", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-24", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a structured table format to map clinical trial progress against specific disease indications.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/25", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-25", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "The diagram illustrates a dose escalation study design with three cohorts leading to the RP2D.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/26", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-26", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "section_divider", "function": "transition", "notes": "The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/27", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-27", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "solution", "function": "present_solution", "notes": "Includes scientific diagrams of molecular pathways and comparative efficacy charts.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/28", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-28", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "traction", "function": "show_traction", "notes": "The slide uses three bar charts to compare IMX-110 performance against benchmarks in mouse models.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/29", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-29", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "traction", "function": "show_traction", "notes": "Includes a process diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/30", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-30", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "traction", "function": "show_traction", "notes": "Includes survival curves (Kaplan-Meier), tumor imaging, and tumor frequency metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/31", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-31", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/32", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-32", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "traction", "function": "show_traction", "notes": "Includes two side-by-side clinical data visualizations (line charts and bar charts) comparing patient outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/33", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-33", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "problem_statement", "function": "frame_problem", "notes": "The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/34", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-34", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "traction", "function": "show_traction", "notes": "The chart is a conceptual visualization of 100% of patients achieving 4 months mPFS.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/35", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-35", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "roadmap", "function": "plan_implementation", "notes": "Shows two parallel clinical tracks: monotherapy and combination with tislelizumab.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/36", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-36", "loopMatches": [ { "to": 36, "from": 22, "name": "Pareto Focus", "slug": "50-pareto-focus", "bestFor": "Resource allocation, problem prioritization, efficiency improvements", "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a", "evidence": "Presentation of market data and clinical development plan", "position": 1, "objective": "Focusing on key markets and opportunities", "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation", "confidence": 0.7, "description": "Show that 80% of results come from 20% of causes to drive prioritization" } ], "arcBeatMatches": [ { "to": 36, "from": 22, "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Discussion of market opportunity and clinical development plan", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/37", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-37", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 37, "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Overview of Immix Biopharma's technology and pipeline", "position": 4, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a process-oriented layout to connect platform capabilities to specific product outputs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/38", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-38", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 37, "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Overview of Immix Biopharma's technology and pipeline", "position": 4, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a process-like flow from the 3 pillars to the specific product applications.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/39", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-39", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 37, "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Overview of Immix Biopharma's technology and pipeline", "position": 4, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 40, "slideType": "solution", "function": "present_solution", "notes": "Includes technical diagrams of the drug construct, comparative histology, and survival curves.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/40", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-40", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 37, "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Overview of Immix Biopharma's technology and pipeline", "position": 4, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "slideType": "traction", "function": "show_traction", "notes": "Includes two sets of charts: tumor volume line graphs and survival curves. References Abouzeid et al. (2013/2014).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/41", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-41", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 37, "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Overview of Immix Biopharma's technology and pipeline", "position": 4, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 42, "slideType": "solution", "function": "present_solution", "notes": "Includes detailed scientific diagrams and references to clinical studies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/42", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-42", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 37, "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Overview of Immix Biopharma's technology and pipeline", "position": 4, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 43, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/43", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-43", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 37, "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Overview of Immix Biopharma's technology and pipeline", "position": 4, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 44, "slideType": "team_bio", "function": "other", "notes": "The slide uses a grid-like layout to present headshots, names, titles, and institutional logos for advisory board members.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/44", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-44", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 37, "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Overview of Immix Biopharma's technology and pipeline", "position": 4, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a749-75ad-9c96-b2ef130e2f41", "docSlug": "810e8355c3b124b062a449d6b3848ba9", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 45, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/45", "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41", "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-45", "loopMatches": [], "arcBeatMatches": [ { "to": 49, "from": 37, "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Overview of Immix Biopharma's technology and pipeline", "position": 4, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a process flow diagram to show the progression of clinical trials for two different treatment regimens.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/38", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-38", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/39", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-39", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 40, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a process-flow style layout to connect platform capabilities to specific clinical assets.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/40", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-40", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a 3-pillar framework to explain the platform, followed by a product-specific breakdown.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/41", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-41", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 42, "slideType": "solution", "function": "present_solution", "notes": "Includes technical diagrams of the drug construct, comparative histology, and survival curves.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/42", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-42", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 43, "slideType": "traction", "function": "show_traction", "notes": "Includes two sets of charts: tumor volume line graphs and survival curves. References specific study methodology in footnotes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/43", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-43", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 44, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a two-part structure: clinical efficacy (top right) and mechanism of action (bottom right).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/44", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-44", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 45, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/45", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-45", "loopMatches": [], "arcBeatMatches": [ { "to": 48, "from": 45, "beatId": "b5cbc254-61b1-4167-96e7-f66088f734e8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "Introduction to Immix Biopharma's team", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 46, "slideType": "team_bio", "function": "other", "notes": "The slide is divided into two sections: ImmixBio Clinical Advisory Board (top) and Select Nexcella Scientific Advisory Board Members (bottom).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/46", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-46", "loopMatches": [], "arcBeatMatches": [ { "to": 48, "from": 45, "beatId": "b5cbc254-61b1-4167-96e7-f66088f734e8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "Introduction to Immix Biopharma's team", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 47, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/47", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-47", "loopMatches": [], "arcBeatMatches": [ { "to": 48, "from": 45, "beatId": "b5cbc254-61b1-4167-96e7-f66088f734e8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "Introduction to Immix Biopharma's team", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 48, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/48", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-48", "loopMatches": [], "arcBeatMatches": [ { "to": 48, "from": 45, "beatId": "b5cbc254-61b1-4167-96e7-f66088f734e8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "Introduction to Immix Biopharma's team", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 49, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/49", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-49", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 50, "slideType": "appendix", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/50", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-50", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 51, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a bar chart to contrast the combined sales of two groups of drugs, illustrating the market size for specific oncology indications.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/51", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-51", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 52, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/52", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-52", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }